AKBA · Insider Trading

Akebia Therapeutics, Inc.

Every open-market purchase and sale reported by AKBA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
1
code P
Sales
12
code S
Reporting Insiders
13
current holders
AKBA — Recent Form 4 Transactions (latest 2026-08-10)
FiledInsiderRole TypeSharesValue
2026-08-10 John P. Butler CEO and President M +350,000 +$220.50K
2026-07-01 Erik Ostrowski SVP, CFO, CBO & Treasurer Sell −56,019 −$62.18K
2026-06-22 Myles Wolf Director A +35,700 —
2026-06-22 Michael W Rogers Director A +35,700 —
2026-06-22 Leanne M Zumwalt Director A +35,700 —
2026-06-22 Ron Frieson Director A +35,700 —
2026-06-22 Cynthia Smith Director A +35,700 —
2026-06-22 Adrian Adams Director A +35,700 —
2026-04-03 Philip J. Vickers Director A +214,400 deriv. —
2026-03-05 John P. Butler CEO and President Buy +69,270 +$86.59K
2026-02-04 Erik Ostrowski SVP, CFO, CBO & Treasurer Sell −34,951 −$48.58K
2026-02-04 Steven Keith Burke SVP, Chief Medical Officer Sell −67,658 −$94.04K
2026-02-04 Richard C Malabre SVP, Chief Accounting Officer Sell −49,524 −$68.84K
2026-02-04 John P. Butler CEO and President MIXED −166,055 −$227.31K
2026-02-04 Nicholas Grund Chief Commercial Officer Sell −84,829 −$117.91K
2026-02-04 Carolyn M. Rucci SVP, Chief Legal Officer Sell −69,772 −$96.98K
2026-02-03 Steven Keith Burke SVP, Chief Medical Officer A +204,000 —
2026-02-03 Carolyn M. Rucci SVP, Chief Legal Officer A +190,000 —
2026-02-03 Nicholas Grund Chief Commercial Officer A +204,000 —
2026-02-03 John P. Butler CEO and President A +743,000 —
2026-02-03 Richard C Malabre SVP, Chief Accounting Officer A +79,000 —
2026-02-03 Erik Ostrowski SVP, CFO, CBO & Treasurer A +204,000 —
2025-07-01 Erik Ostrowski SVP, CFO, CBO & Treasurer Sell −41,314 −$151.62K
2025-06-11 Ron Frieson Director A +35,700 —
2025-06-11 Leanne M Zumwalt Director A +35,700 —
2025-06-11 Steven C Gilman Director A +35,700 —
2025-06-11 Myles Wolf Director A +35,700 —
2025-06-11 Richard C Malabre SVP, Chief Accounting Officer MIXED — −$34.95K
2025-06-11 Michael W Rogers Director A +35,700 —
2025-06-11 Adrian Adams Director A +35,700 —
2025-06-11 Cynthia Smith Director A +35,700 —
2025-06-05 Richard C Malabre SVP, Chief Accounting Officer Sell −13,334 −$47.07K
2025-03-04 Steven Keith Burke SVP, Chief Medical Officer Sell −7,144 −$13.07K
2025-03-04 John P. Butler CEO and President Sell −46,409 −$84.93K
2025-02-04 Richard C Malabre SVP, Chief Accounting Officer MIXED +54,798 −$63.42K
2025-02-04 Erik Ostrowski SVP, CFO, CBO & Treasurer A +194,900 —
2025-02-04 Nicholas Grund Chief Commercial Officer MIXED +139,279 −$116.80K
2025-02-04 John P. Butler CEO and President MIXED +556,750 −$302.93K
2025-02-04 Steven Keith Burke SVP, Chief Medical Officer MIXED +144,394 −$106.06K
2025-01-22 Ron Frieson Director M +20,100 +$9.04K
2024-07-02 Erik Ostrowski SVP, CFO, CBO & Treasurer A +350,000 —
2024-06-10 Cynthia Smith Director A +30,000 —
2024-06-10 Michael W Rogers Director A +30,000 —
2024-06-10 Adrian Adams Director A +30,000 —
2024-06-10 Steven C Gilman Director A +30,000 —
2024-06-10 Ron Frieson Director A +30,000 —
2024-06-10 Leanne M Zumwalt Director A +30,000 —
2024-06-10 Myles Wolf Director A +30,000 —
2024-05-14 Michel Dahan SVP, Chief Operating Officer Sell −34,840 −$43.90K
2024-05-14 Nicole R. Hadas SVP, Chief Legal Officer Sell −12,016 −$15.14K
AKBA — Current Insider Holders
InsiderRole Shares HeldValue
John P. Butler CEO and President 3,878,492 $1.65M
Steven Keith Burke SVP, Chief Medical Officer 948,432 $402.80K
Erik Ostrowski SVP, CFO, CBO & Treasurer 616,616 $261.88K
Carolyn M. Rucci SVP, Chief Legal Officer 588,378 $249.88K
Nicholas Grund Chief Commercial Officer 561,750 $238.58K
Richard C Malabre SVP, Chief Accounting Officer 299,390 $127.15K
Adrian Adams Director 236,200 $100.31K
Michael W Rogers Director 197,429 $83.85K
Cynthia Smith Director 196,633 $83.51K
Myles Wolf Director 169,081 $71.81K
Ron Frieson Director 165,200 $70.16K
Steven C Gilman Director 152,830 $64.91K
Leanne M Zumwalt Director 145,100 $61.62K
AKBA Insider Trading FAQ
Who are the insiders at AKBA?
13 officers, directors and 10%+ beneficial owners currently report holdings in AKBA via SEC Form 4.
Are AKBA insiders buying or selling?
Across the 50 most recent Form 4 filings for AKBA, 1 were open-market purchases (code P) and 12 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is AKBA insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent AKBA filing is dated 2026-08-10.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the AKBA quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.